Bile acid inhibition of P‐glycoprotein–mediated transport in multidrug‐resistant cells and rat liver canalicular membrane vesicles

Roberto Mazzanti, Ornella Fantappié, Yukkio Kamimoto, Zenaida Gatmaitan, Paolo Gentilini, Irwin M. Arias – 1 July 1994 – To study the effect of bile acids on P‐glycoprotein–mediated drug transport, we performed experiments using multidrug resistant cells and rat canalicular membrane vesicles. Cellular accumulation and efflux of rhodamine 123 were measured in drug‐resistant cells by means of computerized quantitative image analysis and fluorescence microscopy.

Beneficial or adverse effects of hepatectomy vs. ethanol injection therapy in RBT‐1 carcinoma of the rat liver

Yasuharu Ikeda, Takashi Matsumata, Hiroshi Hayashi, Akinobu Taketomi, Kazuharu Yamamoto, Keizo Sugimachi – 1 July 1994 – In an attempt to ascertain the possible beneficial or adverse effects of ethanol injection into a hepatic malignant tumor, we carried out a series of experiments using the RBT‐1 carcinoma.

Timing of the first variceal hemorrhage in cirrhotic patients: Prospective evaluation of doppler flowmetry, endoscopy and clinical parameters

Sebastiano Siringo, Luigi Bolondi, Stefano Gaiani, Soccorsa Sofia, Gianni Zironi, Alessandra Rigamonti, Giulio Di Febo, Mario Miglioli, Giancarlo Cavalli, Luigi Barbara – 1 July 1994 – We followed 87 cirrhotic patients with esophageal varices and without previous hemorrhage for a mean period of 24 mo to prospectively evaluate the occurrence of variceal bleeding within (early) or after (late) 6 mo from entry and the contribution of portal Doppler ultrasound parameters to the prediction of early and late hemorrhage.

Favorable effects of total paracentesis on splanchnic hemodynamics in cirrhotic patients with tense ascites

Angelo Luca, Fausto Feu, Juan Carlos García‐Pagán, Wladimiro Jiménez, Vicente Arroyo, Jaime Bosch, Juan Rodés – 1 July 1994 – Total paracentesis is widely used in the treatment of patients with cirrhosis and tense ascites. However, very little information is available regarding its consequences on splanchnic circulation, and its effects on portocollateral blood flow have not been investigated.

Heterogeneity in hepatic transport of somatostatin analog octapeptides

Fricker, Valerie Dubost, Dietmar Schwab, Christian Bruns, Christoph Thiele – 1 July 1994 – Hepatic transport of the synthetic somatostatin analog octreotide—SMS 201–995, ‐Throl—and its novel derivative N‐α‐(α‐D‐glucosyl(1–4)‐1‐deoxy‐D‐fructosyl)‐octreotide—SDZ CO‐611, N‐α‐(α‐D‐glucosyl(1–4)‐1‐deoxy‐D‐fructosyl)‐‐Throl—was studied. In rats SMS 201–995 showed a plasma elimination half‐life of 1.2 ± 0.2 hr; that of SDZ CO‐611 was 1.9 ± 0.3 hours.

Skeletal muscle glycogen content in patients with cirrhosis

Oliver Selberg, Eva Radoch, Gerhard Franz Walter, Manfred James Müller – 1 July 1994 – We investigated stable cirrhotic patients for muscle glycogen content. Muscle biopsy samples were taken of 14 patients after overnight fasting. Electron microscopy showed normal intracellular distribution of glycogen (n=8). Muscle glycogen concentration was 16.5 ± 7.1 gm/kg wet muscle weight (normal range, 10 to 20 gm/kg).

Living donor for liver transplantation

Christoph E. Broelsch, Martin Burdelski, Xavier Rogiers, Matthias Gundlach, Wolfram T. Knoefel, Thomas Langwieler, Lutz Fischer, Astrid Latta, Horst Hellwege, Franz‐Joseph Schulte, Wolff Schmiegel, Martina Sterneck, Heiner Greten, Thomas Kuechler, Gerrit Krupski, Cornelius Loeliger, Peter Kuehnl, Werner Pothmann, Jochen Schulte Am Esch – 1 July 1994 – Since living related liver transplantation was first performed in 1989, more than 150 cases have been performed worldwide, mostly in the United States and Japan.

Liver transplantation for hepatitis B virus—associated cirrhosis: A progress report

David H. Van Thiel, Harlan I. Wright, Stefano Fagiuoli – 1 July 1994 – Because of its importance as an indication for liver transplantation, the epidemiology of chronic hepatitis B disease is presented. Current knowledge relative to the pathobiological mechanisms of hepatitis B virus—related liver disease are presented, followed by a discussion of the treatment modalities currently available for use in hepatitis B virus—related liver disease.

Subscribe to